Skip to main content

A phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53

Objective

Duchenne muscular dystrophy (DMD) is a progressive, lethal muscle degenerative condition arising from the absence of dystrophin in skeletal and cardiac muscles. 65% of DMD boys have out-of-frame deletions. Modulation of pre-mRNA splicing by exon skipping is the most promising molecular intervention in DMD. 2 Phase Ib and 2 Phase IIa clinical trials (MDEX Consortium in collaboration with Sarepta Therapeutics; a Dutch Consortium) demonstrated that delivery of antisense oligonucleotides (AOs) to mediate exon skipping of exon 51 were able to return specific DMD mutations in-frame (~13% of all mutations) leading to new dystrophin protein expression after intramuscular and systemic delivery. The Dutch study of repeated 2-O-methylated phosphorothioate (2OMe) AO administration suggested limited efficacy after 5 weeks of treatment. Our MDEX Consortium study using a morpholino (PMO) AO demonstrated a clear dose response, robust dystrophin restoration and reduction of muscle inflammation after 12 weeks at doses up to 20mg/Kg, with no drug related adverse events. This, and preclinical studies focused on level of protein expression, clearly indicate that PMO have a superior therapeutic index compared to 2OMe. New PMOs are needed to target other DMD mutations. We will develop a PMO to skip exon 53 and perform a clinical trial in DMD boys using a world leading pan-European consortium. This will allow us to advance this class of PMO therapy in DMD by i. assessing the safety and efficacy of targeting another exon; ii. exploring the use of non-invasive techniques to monitor dystrophin restoration. This new PMO will be administered over 12 weeks in 3 groups, each of 4 DMD boys, receiving between 4 to 30mg/kg or placebo. If well tolerated, all boys will be treated for another 24 weeks at a dose of 30mg/kg. Safety and dystrophin restoration in a muscle biopsy at the end of this period will be the study endpoints. MRI, MRS and serum miRNA will be used to monitor muscle pathology non-invasively.

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Coordinator

UCL Elizabeth Garrett Anderson Institute for Women’s Health
Address
Gower Street
WC1E 6BT London
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 147 708,62
Administrative Contact
Michael Browne (Mr.)

Participants (9)

ASSOCIATION INSTITUT DE MYOLOGIE
France
EU contribution
€ 447 367,99
Address
Boulevard De L Hopital 47-83
75651 Paris
Activity type
Research Organisations
Administrative Contact
Christelle Gaultier (Mrs.)
CONSULTANTS FOR RESEARCH IN IMAGING AND SPECTROSCOPY SCRL
Belgium
EU contribution
€ 168 373,88
Address
Chaussee De Lannoy 31
7503 Tournai
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Raymond Gilles (Dr.)
UNIVERSITY OF NEWCASTLE UPON TYNE
United Kingdom
EU contribution
€ 445 316
Address
Kings Gate
NE1 7RU Newcastle Upon Tyne
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Aleona Blinova (Ms.)
UNIVERSITA CATTOLICA DEL SACRO CUORE
Italy
EU contribution
€ 204 600
Address
Largo Gemelli 1
20123 Milano
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Filippo Leone (Mr.)
CHARLES RIVER LABORATORIES PRECLINICAL SERVICES EDINBURGH LTD
United Kingdom
EU contribution
€ 326 100,35
Address
Elphinstone Research Centre
EH33 2NE Tranent
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ernest Larnach (Mr.)
ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE
United Kingdom
EU contribution
€ 194 941
Address
Egham Hill University Of London
TW20 0EX Egham
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Rosemary Greaves (Ms.)
SYSNAV SAS
France
EU contribution
€ 316 100
Address
Rue De Montigny 57
27200 Vernon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Eric Dorveaux (Dr.)
SAREPTA THERAPEUTICS INC CORPORATION
United States
EU contribution
€ 1 966 527,85
Address
Monte Villa Parkway - Suite 101 3450
98021 Bothell Wa
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Edward Kaye (Dr.)
GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST
United Kingdom
EU contribution
€ 295 388,38
Address
Great Ormond Street
WC1N 3JH London
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Anna Ferrant (Dr.)